Cullen/Frost Bankers, Inc. Argenx Se Transaction History
Cullen/Frost Bankers, Inc.
- $7.23 Billion
- Q3 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Argenx Se stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 53 shares of ARGX stock, worth $32,857. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53
Previous 10
430.0%
Holding current value
$32,857
Previous $4,000
600.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ARGX
# of Institutions
400Shares Held
30.9MCall Options Held
376KPut Options Held
489K-
Price T Rowe Associates Inc Baltimore, MD5.82MShares$3.61 Billion0.36% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.18 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.54 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$1.05 Billion0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$768 Million10.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $34.3B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...